Summary of Key Points
AstraZeneca reported overall growth in its global performance for the first half of this year (a 6% increase in total revenue and a 11% increase in core profits). However, revenue from China decreased by 5% year-on-year, which dragged down the growth rate in emerging markets, which only reached 3%. The decline in China was mainly due to poor performance of its three key products: dapagliflozin (eliminated from national procurement programs), Tagrisso (increased local competition), and olaparib (pressured by generic drugs). Nevertheless, the company also has bright spots—two new drugs have achieved growth rates of over 30% in emerging markets, and it is continuing to increase its investment in the Chinese market (planning to invest over 100 billion yuan by 2030).
I. Stable Global Performance, but China Becomes a Drag
AstraZeneca’s global business performed well in the first half of the year: total revenue reached $30.672 billion, up 6% year-on-year; core profits were $10.5 billion, up 11%, driven mainly by growth in its oncology and rare diseases segments. However, when looking at regions, emerging markets, including China, held back the company’s overall performance. Growth rates in the United States (42%) and Europe (22%) were both 8%, while in emerging markets they were only 3%. China accounted for approximately 11% of the company’s total revenue and saw a year-on-year decrease of 5%, which was the main reason for the lower growth rate in these regions.
II. Decline in Chinese Revenue Due to Poor Performance of Three Key Products
The decline in Chinese revenue was primarily due to the underperformance of three former cash-carrying products:
1. Dapagliflozin (blood sugar medication): The world’s largest-selling product, but its revenue decreased by 11% in the first half of this year. In China, it was not selected for the national procurement program due to AstraZeneca’s high bid, resulting in the loss of the public hospital market. Additionally, the emergence of generic drugs reduced sales.
2. Tagrisso (lung cancer medication): The world’s second-largest selling product and a leader in the oncology sector, but its growth in the Chinese market was weak. This was due to the increasing number of third-generation EGFR-TKI drugs in China, intensifying competition and slowing down the overall market growth, which weakened Tagrisso’s dominant position.
3. Olaparib (oncology medication): Also affected by the pressure from generic drugs, its growth was hindered.
III. Bright Spots in Emerging Markets: Two New Drugs as New Drivers
Despite the challenges in China, AstraZeneca has seen positive results in emerging markets:
- Duvallumab (immunotherapy drug) and Trastuzumab (precision cancer medication): These two new oncology drugs have achieved growth rates of over 30% in emerging markets. They not only serve as drivers of growth for these regions but also contribute to the company’s overall oncology business expansion.
IV. AstraZeneca Does Not Give Up on China; Instead, It Increases Investment for the Future
Despite the temporary setbacks in China, AstraZeneca is increasing its efforts:
1. Long-term investment: The company announced plans to invest over 100 billion yuan in China by 2030 to develop next-generation innovative drugs.
2. Acquisition of local pipelines: Recently, AstraZeneca spent $1.9 billion to acquire the overseas rights to a Chinese biopharmaceutical’s chronic obstructive pulmonary disease (COPD) drug and another $1.5 billion to acquire the global rights to Dizhe Pharmaceutical’s suvorelinitib, addressing its weaknesses in the respiratory therapy area.
3. Construction of production facilities: AstraZeneca is building new factories in China to ensure supply.
These actions indicate that the company remains optimistic about the long-term potential of the Chinese market and aims to regain lost market share through innovation and localization strategies.
Conclusion
AstraZeneca is facing short-term difficulties in China due to the impact of national procurement programs and local competition, but its global fundamentals are strong, with new drugs driving growth. Whether it can reverse the decline in the Chinese market will depend on whether these new initiatives can generate significant momentum quickly.